This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bernier, M.-O. Articles by Hejblum, G. Search for Related Content PubMed PubMed Citation Articles by Bernier, M.-O. Articles by Hejblum, G.

Survival and Therapeutic Modalities in Patients with Bone Metastases of Differentiated Thyroid Carcinomas

Departments of Nuclear Medicine (M.-O.B., L.L., A.A.), Pathology (C.H.), General and Gastrointestinal Surgery (F.M.), Endocrinology (G.T.), Neuroradiology (J.C.), and Orthopedic Surgery (E.E., G.S.), Hôpital Pitié-Salpêtrière, 75013 Paris, France; Epidemiology and Information Science, INSERM, U-444, Université Paris 7 (J.-Y.M.), 75005 Paris, France; and Quantitative Medical Imaging Unit, INSERM, U-494, Hôpital Pitié-Salpêtrière (M.-O.B., L.L., G.H., A.A.), 75651 Paris, France

Address all correspondence and requests for reprints to: Dr. Marie O. Bernier, Service de Médecine Nucléaire, Hôpital Pitié-Salpêtrière, 47–83 boulevard de l’Hôpital, 75651 Paris Cedex 13, France. E-mail: gilles.hejblum{at}imed.jussieu.fr

Data for patients with bone metastases (BMs) of differentiated thyroid carcinoma (DTC) were retrospectively studied to identify factors associated with survival. We especially studied the impact of therapies. Among the 1977 patients followed for DTC in our department from 1958 to 1999, 109 (77 females and 32 males; age range, 20–87 yr) presented BMs. All patients except 1 underwent total thyroidectomy, followed by radioiodine therapy (3.7 gigabecquerels) in 95 cases. Survival rates at 5 and 10 yr were 41% and 15%, respectively. Univariate analyses indicated that a young age at BM discovery (P < 0.005) and the discovery of BM as a revealing symptom of DTC (P < 0.05) were features significantly associated with improved survival as well as radioiodine therapy (P < 10^-4) and BM complete surgery (P < 0.02). Using multivariate analysis, the detection of BMs as a revealing symptom of thyroid carcinoma (P < 0.0005), the absence of metastasis appearance in other organs than bones during the follow-up (P < 0.03), the cumulative dose of radioiodine therapy (P < 0.0001), and complete BM surgery in young patients (P < 0.04) appeared as independent prognostic features associated with an improved survival.

This article has been cited by other articles:

				H. Raef, T. Dahhan, M. Ahmed, M. Mubarak, T. Rana, and A. Tulba Recurrent thyroid storm induced by heretofore unrecognised causes in a patient with thyroid cancer BMJ Case Reports, April 14, 2009; 2009(apr14_1): bcr0720080442 - bcr0720080442. [Abstract] [Full Text]

				X. Xiao, L. Ning, and H. Chen Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors Mol. Cancer Ther., February 1, 2009; 8(2): 350 - 356. [Abstract] [Full Text] [PDF]

				P. Zanotti-Fregonara, D. Rubello, and E. Hindie Bone Metastases of Differentiated Thyroid Cancer: The Importance of Early Diagnosis and 131I Therapy on Prognosis J. Nucl. Med., November 1, 2008; 49(11): 1902 - 1903. [Full Text] [PDF]

				M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF]

				E. Hindie, P. Zanotti-Fregonara, I. Keller, F. Duron, J.-Y. Devaux, M. Calzada-Nocaudie, E. Sarfati, J.-L. Moretti, P. Bouchard, and M.-E. Toubert Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome Endocr. Relat. Cancer, September 1, 2007; 14(3): 799 - 807. [Abstract] [Full Text] [PDF]

				C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J. P. Travagli, B. Caillou, M. Ricard, J. D. Lumbroso, F. De Vathaire, et al. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2892 - 2899. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803. [Full Text] [PDF]

				A. Rouxel, G. Hejblum, M.-O. Bernier, P.-Y. Boelle, F. Menegaux, G. Mansour, C. Hoang, A. Aurengo, and L. Leenhardt Prognostic Factors Associated with the Survival of Patients Developing Loco-Regional Recurrences of Differentiated Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5362 - 5368. [Abstract] [Full Text] [PDF]